D-dimer

D-dimer is a fibrin degradation product. When coagulation is activated and clot forms, fibrinolysis produces D-dimer as a byproduct. A negative high-sensitivity D-dimer, in the right population and with the right pathway, can help exclude acute thrombosis without imaging.

That is the test's clinical power — and its limit.

A positive D-dimer does not establish a diagnosis. It tells you that coagulation and fibrinolysis have been activated somewhere. That can happen in PE, DVT, dissection, infection, inflammation, malignancy, pregnancy, surgery, trauma, hospitalization, and many other states.

The test rules out far more reliably than it rules in.

D-dimer is only useful when it is ordered in the right clinical context. The result does not interpret itself.

In a patient with low or intermediate pre-test probability for PE or DVT, a negative high-sensitivity D-dimer — using the validated assay and pathway — can safely end the workup without imaging.

In a patient with high pre-test probability, a negative D-dimer does not exclude the diagnosis. Proceed to definitive imaging according to the clinical pathway.

Ordering D-dimer without first estimating pre-test probability is the most common source of misinterpretation. The number means something different depending on where the patient sits on the probability spectrum.

D-dimer rises in any state where coagulation and fibrinolysis are activated. This is biologically real — the elevation is not a false positive in the traditional sense.

Common contexts that raise D-dimer independent of PE or DVT include increasing age, infection and inflammation, malignancy, pregnancy, recent surgery or trauma, hospitalization, and other acute systemic illness.

In populations where baseline D-dimer elevation is common, a positive result adds little diagnostic specificity. The result may be real and still be diagnostically nonspecific.

This is why specificity falls in older patients, hospitalized patients, and those with active comorbidities. The test was not designed to be used indiscriminately in these populations.

For patients older than 50 years, age-adjusted thresholds can improve specificity while preserving safety when used within a validated diagnostic pathway. A commonly used approach is age × 10 µg/L (equivalent to ng/mL FEU) for patients older than 50. Always confirm the laboratory's units and assay.

Clinical probability-adjusted strategies such as YEARS and PEGeD alter the threshold based on defined clinical criteria. These strategies should be used as complete validated pathways rather than mixing individual components.

Do not apply age-adjusted thresholds outside of validated pathways. The safety data comes from the pathway as a whole — not from the threshold in isolation.

D-dimer assays and reporting units vary. FEU (fibrinogen equivalent units) and DDU (D-dimer units) use different concentration units and have different numeric thresholds. Never apply a memorized numeric cutoff without confirming the laboratory method and local pathway.

High-sensitivity assays have different performance characteristics than conventional assays. The validated pathway specifies which assay and which threshold apply.

When in doubt, confirm with the laboratory and the institutional protocol before using the result to guide a clinical decision.